This company has a phase 3 clinical trial update due in Q1 2021. Hold until the release or hold long term. Now appears to be a decent entry point. Make sure you sell after the 31st if it doesn't explode. Good Luck!
Pelaton Interactive has started to rise up out of its wedge it has been forming. This usually is a good sign and could mean big gains. It is also staring to come off of support, which is another green flag. Good Luck!
Tesla shares are currently sitting on support. Look for a bounce this week. Target the $850-$900 zone. Good Luck!
Atossa Therapeutics has potentially come out with a new and innovative treatment for cancer. It isn't a sure thing, but once the public hears more about the drug and they start to get into late-stage clinical trials, this stock could skyrocket. Good Luck!
Palantir tech has found its current support level. Also, they are currently riding on the bottom of the RSI, which means they are likely to push back up to the top. Target around $40 for easy short term gains.
Genetics could be the technology of tomorrow. Using genetic sequencing, scientists have been able to make new medications for diseases that work very effectively. They have also been able to use genetics to study how certain diseases impact people. This stock has the potential to rise much more. Target the $130-$150 zone.
As you can see, AAPL has fallen down to 135, which happens to be there current support level. Look to hold for a couple of days as it tries to push off that support. Also, the MACD indicator looks very bullish for this 1h chart as it appears to have just crossed with upward momentum. Target $145. You could also hold long term, AAPL is not going away any time soon....
Aprea Therapeutics dropped over 70% in December, and now that it shows strong upside, this stock is pure gold. It is riding around 6.67 right now, and I think that it has the potential to reach up to 30$ this year. I will let you know if you should sell. I have already entered here, but you could wait to buy until it drops into the lower half of the Linear...
Please don't miss out on this one. If you are already a follower of me, you know that phase 3 trial data means very good things. Take a look at my idea on GMDA. like and follow for more picks like this!
After losing most of its value, OVID sort of did nothing for the past month. However, recently it showed strong upside which makes me think it could bounce back eventually. If you like this idea, take a look at my idea on APRE and also look at UBX and how they bounced back. Target the $6 zone.
On the Ninth GMDA will present Data for a new drug they are making. Buy on Friday and sell on Tues at the market open for easy gains. The stock will be volatile during the day, but it may be a good idea to reenter at the market close (The presentation is at 4:45 PM EST).
What if I told you you could slow your aging dramatically by simply taking a pill? UBX has been working on this for a very long time, and they have showed promise in their trials. The risk could be somewhat high, but you could be looking at a potential 20,000% upside if they are successful.
ROKU shares broke the top line of this linear regression channel on Friday, which means you can expect them to fall this week.
SiTime Corporation is still producing strong products that help with technologies across the board. They are still a stellar long term investment, but as you can see in the chart, SITM shares have capped off at the top of the linear regression channel. Look to pull out Monday and re enter once they fall below 110.
TSLA has been surging big, but their shares could be capping off soon. Shares reached $880 on Friday, which broke through their 2-month highs trendline. Shares may fall as low as $700 this week. **Used script by LonesomeTheBlue**
Clean Energy has changed the way the world fuels its vehicles. Natural Gas is becoming more available to countries around the world, and many are already using it for their public transportation vehicles. Look to target the $14-$15 zone. There is a chance that CLNE will fall next week, but most likely the uptrend will continue.
AVINGER Inc has been rising quite a lot this year, but this is only the beginning. Look to target the $1.50-$2.00 zone this year.
Zymeworks is releasing a new drug, ZW25, to treat HER2-expressing Gastroesophageal Adenocarcinoma. The phase one trials for this drug done, and the data for the trials will be released on January 15, 2021. For optimal gains, buy a week in advance and sell the day of the data release. Again, the data will be released 11:30-12:15 EST on January 15, 2021 . Like and...